Resources

Terry Gregg, CEO, Dexcom, talks about how blood glucose monitoring in cars and getting updates while driving might not be a good idea but the potential prevention of traffic accidents is definitely something to look at….

Terry Gregg, CEO, Dexcom, talks about the reduction in hypo’s with better monitoring technology. This can also result in significant cost savings and Dexcom will hopefully be starting a study later this year examining the cost components of their products, and how to ensure that they are “part of the …

Terry Gregg, CEO, Dexcom, reviews some of the data that he has seen on the healthcare cost savings that continuous glucose monitoring technology can bring. Much of this comes from preventing hypoglycemic episodes that can result in an average hospital stay bill of around $17.000. But he also mentions that …

Terry Gregg, CEO, Dexcom, answers Steve’s questions about using CGM technology to help type 2 diabetes patients learn about blood sugar control. He reveals that he frequently talks about the greater role in behavior modification that CGM could play in helping not only those diagnosed with diabetes but perhaps even …

Terry Gregg, CEO, Dexcom, discusses the current landscape of reimbursement for CGM technology. Although insurance companies were initially slow to catch on for approving CGM devices for type 1’s, there has been a shift and approvals seem to be improving. He is also sees the overall market increasing as more …

Terry Gregg, CEO, Dexcom, shares his thoughts on a “cure” for diabetes, commenting that 20 years ago, he was told it would happen in 5-7 years. At this time he believes it is still a way off and that, “Realistically, we’ll proobably find a way to prevent it before we …

Terry Gregg, CEO, Dexcom, talks about the increases in CGM accuracy which Dexcom is working towards, as well as the cooperative efforts they are involved in with working towards an effective artificial pancreas. He says that one of the goals of Dexcom is to “eliminate fingersticks” and they are getting …

  In this week’s series of Homerun Slides, we take a more detailed look at the most recently approved SGLT2 inhibitor, dapagliflozin, and then explore some of the other SGLT2 inhibitors which are on the horizon….

Rudy Bilous MD, FRCP Richard Donnelly MD, PHD, FRCP, FRACP   Islet structure and function Insulin is synthesized in and secreted from the β-cells within the islets of Langerhans in the pancreas. The normal pancreas has about 1 million islets, which constitute about 2-3% of the gland’s mass. All of the islet …

by Dr. Sheri Colberg, Ph.D., FACSM Recently, I had to opportunity to view some of the ongoing trials of one of the many "artificial pancreas" (AP) systems in development, and it was an eye-opening and somewhat disappointing experience. As an exercise physiologist, avid recreational exerciser, and person living with type …